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Giant cell myocarditis masquerading as orbital
myositis with a rapid, fulminant course necessitating
mechanical support and heart transplantation
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Division of Cardiology, Department of Medicine, UCLA Medical Center, Los Angeles, CA90095, USA
Abstract
Giant cell myocarditis (GCM), a rapidly progressive inflammation of the myocardium, is associated with fulminant heart failure,
refractory ventricular arrhythmias, and conduction system abnormalities. Few case reports have noted orbital myositis as the
initial clinical presentation. Our case demonstrates a unique presentation of GCM with only ocular symptoms, which unlike
prior studies, rapidly progressed to heart failure, tachyarrhythmias, and conduction disease. Our case necessitated quick rec-
ognition and treatment with mechanical support making this the first known case of GCM with successful placement of
biventricular assist devices and ultimately with heart transplantation.
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Introduction
Giant cell myocarditis (GCM) is a rare and rapidly progres-
sive disorder with inflammation of the myocardium often
associated with fulminant heart failure, refractory ventricu-
lar arrhythmias, conduction system abnormalities, and/or
angina-like symptoms. While this immune-mediated disease
generally carries a poor prognosis, early recognition and di-
agnosis with endomyocardial biopsy, aggressive treatment
with immunosuppressive therapy, and timely involvement
of heart failure teams for evaluation of transplant or me-
chanical assist devices can improve outcomes. Roughly,
20% of cases are associated with systemic autoimmune dis-
ease, but only rare case reports1–4 have noted orbital myo-
sitis as the initial clinical presentation. Our case
demonstrates a unique presentation of GCM with only ocu-
lar symptoms that rapidly progressed to heart failure, tachy-
arrhythmias, and conduction disease. Prompt recognition
allowed early intervention with immunosuppression, place-
ment of biventricular assist devices, and eventual successful
heart transplantation.
Case report
A 50-year-old man with well-controlled rheumatoid arthritis
on Leflunomide presented to our hospital with sudden onset
right-sided diplopia and 2 weeks of progressive
ophthalmoplegia and ptosis. MRI of the orbits showed multi-
focal extraocular muscle hypertrophy suggestive of orbital
inflammation (Figure 1). Presenting vitals were significant
for tachycardia (heart rate 110 bpm) and relative hypoten-
sion (98/59). His troponin was elevated to 0.68 ng/mL on ad-
mission. Initial ECG showed sinus tachycardia with RSR’
pattern in lead V1, inferior Q waves with sub-millimetre ST-
segment elevation (Figure 2). Echocardiogram showed a
non-dilated left ventricle, reduced left ventricular ejection
fraction of 30–35% with global hypokinesis, and concentric
left ventricular hypertrophy (Figure 3). Given the lack of sig-
nificant cardiovascular symptoms, the initial thought was
demand-related troponin elevation; thus, noninvasive risk
stratification was obtained. Pharmacologic stress myoview
demonstrated no scintigraphic evidence of infarct or stress-
induced ischemia. On hospital day 2, plasmapharesis was
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initiated for the presumed autoimmune orbital symptoms.
On hospital day 3, he complained of diaphoresis and chest
heaviness and was found to have high-grade atrioventricular
block with 6 s ventricular pauses. He developed syncope with
an asystolic rhythm for 20 s requiring a brief episode of chest
compressions with quick recovery of spontaneous circulation.
He underwent emergent placement of a transvenous pacing
wire. Cardiac catheterization was notable for no significant
coronary artery disease; however, because of low cardiac out-
put, mechanical circulatory support with an Impella device
was instituted, which resulted in hemodynamic normaliza-
tion. Intravenous steroids were initiated for a likely inflamma-
tory process, and on day 5, he developed ventricular
tachycardia (heart rate 250 bpm) requiring cardioversion
and antiarrhythmic therapy. Endomyocardial biopsy was per-
formed that demonstrated numerous nucleated giant cells
within an inflammatory infiltrate consistent with GCM (Figure 4).
Immunosuppressive therapy including steroids (prednisone
60 mg daily, mycophenolate mofetil (1 g twice daily), and
tacrolimus (0.5 g twice daily) were started. The Impella
was weaned on day 10; however, the patient continued
to require inotropic support. Serial echocardiography
showed worsening biventricular systolic function, which
prompted elective placement of HeartWare HVAD
(HeartWare ventricular assist device) biventricular assist devices
Figure 1 MRI of orbits showing multifocal extraocular muscle enlarge-
ment (arrows) and signal abnormality suggestive of orbital inflammatory
disease.
Figure 2 Electrocardiogram showing sinus vs. atrial tachycardia with an incomplete right bundle branch block. There are q waves in the inferior and
anterior leads suggestive of infarction.
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on hospital day 23 (Figure 5). Six days later, he was listed for
heart transplant and by day 31, he underwent successful heart
transplantation. He remained on standard post-transplant im-
munosuppression with no evidence of recurrence in the newly
transplanted heart and gradual improvement of his ocular symp-
toms although still with residual deficits at 3 month follow-up.
Discussion
Giant cell myocarditis presents with fulminant heart failure
(41–75%), refractory ventricular arrhythmias (14–17%),
angina-like symptoms (6–9%), and/or conduction system
abnormalities (5–28%).5,6 While the exact pathogenesis is
unknown, CD-4 T lymphocyte-mediated inflammation of the
myocardium is suggested.5,7 There is a 20% incidence of
concomitant autoimmune disorder, but only a handful of
cases are associated with orbital myositis.
Diagnosis relies on high clinical suspicion and biopsy-
proven evidence of giant cells within cardiac tissue with a
cautious realization of the high rate of false-negative biopsy
results (sensitivity 68% with single biopsy).8 Imaging such as
cardiac MRI or 18FDG-PET with SPECT imaging may aide in
localization of inflammatory infiltration resulting in targeted
Figure 3 Two-dimensional echocardiography in the parasternal long (left) and parasternal short (right) axes showing thickened myocardium (arrows).
Cine images (see Supporting Information, Movies S1–S3) demonstrate globally reduced ejection fraction around 30–35% without significant chamber
enlargement. IVSd, interventricular septum at diastole; PWd, posterior wall at diastole.
Figure 4 Endomyocardial biopsy demonstrating inflammatory infiltration of cardiac myocardium with a haematoxylin and eosin stain (left). Magnified
view (right) demonstrating numerous giant cells within inflammatory infiltrate consisting of lymphocytes, histiocytes, and eosinophils.
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biopsies.8 Treatment requires a multimodality approach with
pharmacologic interventions and mechanical support devices.
Survival without treatment is dismal with a rate of death or
cardiac transplantation of 89% and a medial survival of about
5.5 months from symptom onset.5 With combination immu-
nosuppressive agents, survival without need for transplant
is drastically improved with a 1 year survival of 77–80% and
a 5 year survival of 58%.6,8 However, most studies have
shown that the majority of patients ultimately require trans-
plantation or permanent ventricular support.9 For this rea-
son, timely referral to centres with a heart failure service
and capability of advanced heart failure support is essential.
Importantly, recurrence in the transplanted heart is also re-
ported and warrants close follow-up and routine biopsies.5,8
In our case, the patient presented with ocular symptoms,
initially thought to be autoimmune in aetiology although
extensive autoimmune and infectious workups, was
unrevealing. While GCM was not initially suspected upon pre-
sentation, there were critical clues from the onset that sug-
gested cardiac involvement. The initial abnormalities on the
electrocardiogram, persistent tachycardia, hypotension, and
troponin elevation were important early clinical manifesta-
tions. While ocular and/or endomyocardial biopsy was con-
sidered, treatment was initiated because of anticipated
delay in transferring the patient to our quaternary referral
centre. Within 3 days of hospital presentation, the patient
showed signs of high-degree atrioventricular block, cardiomy-
opathy on echocardiography, and elevated left-sided filling
pressures requiring mechanical support. Prompt initiation of
inotropic medications and mechanical support with the
Impella device likely avoided hemodynamic compromise.
The rapidly accelerating course demanded further cardiac in-
vestigation with endomyocardial biopsy with a leading diag-
nosis of GCM. Previous studies cited steroids, azathioprine,
and cyclosporine as immunosuppressive agents for treatment
of GCM;5,6,8 however, after discussion with experts in GCM,
mycophenolate mofetil and tacrolimus were used given the
high likelihood of heart transplant in our case.
This case is particularly unique due to the rarity of initial
presenting symptom of orbital myositis, use of Impella as a
mechanical bridge, and rapidity of cardiovascular decline.
Few case reports of orbital myositis in adult patients have
been linked to GCM,1–4 with orbital myositis predating car-
diac symptoms by months to years (1 month–3 years). While
rare, these case studies demonstrate a substantial link be-
tween the two diagnoses. Another unique aspect of our case
is the use of a percutaneous mechanical assist device as a
temporizing measure. To our knowledge, there is only one
previous case report in which a patient with GCM was suc-
cessfully implanted with an Impella device as a bridge to
more permanent left ventricular support.10 Additionally, this
is the first reported case of successful implantation of
HeartWare biventricular HVAD in a patient with biventricular
failure due to GCM.
Patients with autoimmune disease including orbital myosi-
tis and any sign of cardiac abnormality should be thoroughly
investigated. High index of suspicion and close vigilance of
typical cardiac manifestations will give physicians an advan-
tage in diagnosing and treating this time-sensitive disease.
The rapidity of disease acceleration and fulminant course un-
derscore the importance of aggressive treatment including
pharmacologic and mechanical assistive support devices
and/or orthotopic cardiac transplantation. Early recognition
of orbital myositis as a potential early sign of GCM as well
as timely goal-directed therapies can significantly improve
outcomes.
Conflict of interest
None declared.
Supporting information
Supporting information may be found in the online version of
this article.
Movie S1. Cine-echo image in parasternal long axis.
Movie S2. Cine-echo image in parasternal short axis.
Movie S3. Cine-echo image in apical four chamber view.
Figure 5 Portable chest X-ray showing biventricular HeartWare ventricu-
lar assist devices.
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